• Frost Radar—Global RNA Delivery Technologies, 2021
    A benchmarking system to spark companies to action - innovation that fuels new deal flow and growth pipelines

    Click image to view it in full size

    The year 2018 was a breakthrough period for RNA therapeutics as the first RNA therapy received approval from the FDA. In the wake of the COVID-19 pandemic, RNA vaccines have witnessed immense progress and acceptance globally. These events have contributed massively to growth across the RNA therapeutics market.

    Currently, several RNA therapeutics are in different stages of development, including mRNA, tRNA, siRNA, and RNAi therapies, but mostly concentrated in the early pre-clinical and clinical stages. The popularity of RNA therapeutics is demanding the need to establish efficient delivery systems that can overcome current challenges, such as early degradation of RNA therapeutic molecules, toxicity, and non-target specificity.

    This RNA Delivery Technologies, 2021 Frost Radar™ covers companies that are developing robust delivery systems for the rapidly growing RNA therapies and adopting the latest advances in nanoscience and chemically modified delivery systems. These delivery systems are critical to achieving the final results in the efficiency of RNA therapeutics.


    Take your first step towards achieving growth-centric solutions with our Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.

    Access Research Via